Shorla Drug Patent Portfolio
Shorla owns 3 orange book drugs protected by 4 US patents Given below is the list of Shorla's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11975013 | Stable formulations comprising thiotepa | 16 Aug, 2041 | Active |
| US11957681 | Liquid dosage forms of Imatinib | 27 Apr, 2040 | Active |
| US11129833 | Methotrexate formulation | 28 Oct, 2035 | Active |
| US11771701 | Methotrexate formulation | 29 Oct, 2034 | Active |
Latest Legal Activities on Shorla's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Shorla.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 28 Mar, 2025 | US11129833 |
| Electronic Review | 07 Jun, 2024 | US11975013 |
| Mail Patent eCofC Notification | 28 May, 2024 | US11957681 |
| Email Notification | 28 May, 2024 | US11957681 |
| Recordation of Patent eCertificate of Correction | 28 May, 2024 | US11957681 |
| Patent eCofC Notification | 28 May, 2024 | US11957681 |
| Email Notification | 15 May, 2024 | US11957681 |
| Mail Certificate of Correction Memo | 14 May, 2024 | US11957681 |
| Post Issue Communication - Certificate of Correction | 09 May, 2024 | US11957681 |
| Certificate of Correction Memo | 08 May, 2024 | US11957681 |
| Patent Issue Date Used in PTA Calculation | 07 May, 2024 | US11975013 |
| Mail Patent eGrant Notification | 07 May, 2024 | US11975013 |
| Recordation of Patent eGrant | 07 May, 2024 | US11975013 |
| Email Notification | 07 May, 2024 | US11975013 |
| Patent eGrant Notification | 07 May, 2024 | US11975013 |
Shorla's Family Patents
Shorla Drug List
Given below is the complete list of Shorla's drugs and the patents protecting them.
1. Imkeldi
Imkeldi is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11957681 | Liquid dosage forms of Imatinib |
27 Apr, 2040
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Imkeldi's drug page
2. Jylamvo
Jylamvo is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11129833 | Methotrexate formulation |
28 Oct, 2035
(9 years from now)
| Active |
| US11771701 | Methotrexate formulation |
29 Oct, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jylamvo's drug page
3. Tepylute
Tepylute is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11975013 | Stable formulations comprising thiotepa |
16 Aug, 2041
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tepylute's drug page